Approved UK AML Treatments Information on UK approved AML treatments: Intensive chemotherapyExpandDA (Daunorubicin and cytarabine) DA + Mylotarg (Gemtuzumab ozogamicin) DA + Midostaurin DA + Quizartinib Liposomal cytarabine-daunorubicin (Vyxeos) FLAG-Ida HiDaC (High dose cytarabine) Less intensive and targeted therapiesExpandVenetoclax and azacitidine Venetoclax and low dose cytarabine Ivosidenib and azacitidine Gilteritinib Azacitidine injections (Vidaza) Low dose cytarabine (LDAC) Hydroxyurea Maintenance therapiesExpandOral azacitidine tablets (Onureg) Sorafenib Allogeneic stem cell transplantationExpandNHS Commissioning Service specifications for adult haematopoietic stem cell transplant Outcomes of older AML patients aged 60-70 receiving transplants: the NCRI AML16 trial (Russell et al 2022) British Society of Blood and Marrow Transplantation and Cellular Therapy Best practice consensus guidelines on management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation (Clark et al 2023) Clinical Resources Guidelines & Clinical Resources AML Relapse (MDT) Approved UK AML Treatments
